Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4.

Journal of viral hepatitis - 1 Oct 2008

Martín-Carbonero L, Puoti M, García-Samaniego J, De Luca A, Losada E, Quinzan G, Bruno R, Mariño A, González M, Núñez M, Soriano V

Abstract excerpt

SUMMARY: Hepatitis C virus (HCV) genotypes 1 and 4 respond less well to pegylated interferon (pegIFN) plus ribavirin (RBV) therapy. For this reason most studies merge these two genotypes when assessing virological response. However, in most trials the HCV genotype 4 population is rather small, and conclusions are mainly derived from what occurs in HCV-1 patients. All HCV-4 patients coinfected with HIV who...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Therapy, Combination
Share to Hepatitis C, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Polyethylene Glycols

Share to Ribavirin

Source

Identifiers

PMID: 18637070
DOI: 10.1111/j.1365-2893.2008.01015.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4.PMID 18637070Read ↗

Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4.Semantic proximity Read ↗

Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection.Semantic proximity Read ↗

Hepatitis C virus genotype 4 responds better to pegylated interferon with ribavirin than genotype 1 in HIV-infected patients.Semantic proximity Read ↗

Hepatitis C genotype 4 therapy: increasing options and improving outcomes.Semantic proximity Read ↗

Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4.Semantic proximity Read ↗

A randomized trial of 24 versus 48 weeks of peginterferon alpha-2a plus ribavirin in Egyptian patients with hepatitis C virus genotype 4 and rapid viral response.Semantic proximity Read ↗

[Results of the treatment of chronic hepatitis C genotype 4--a comparative analysis with genotype 1].Semantic proximity Read ↗

Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4.Semantic proximity Read ↗

Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4.Semantic proximity Read ↗

Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4.Semantic proximity Read ↗

Hepatitis C virus genotype 4 therapy: progress and challenges.Semantic proximity Read ↗

Treatment of chronic hepatitis C genotype 4 with peginterferon alpha-2a plus ribavirin.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.